Overall, the HA viscosupplementation market will negatively impacted by the COVID-19 pandemic due to the elective and less urgent nature of these procedures. Once the market stabilizes, the global market for HA viscosupplementation will exhibit modest growth through 2029. While premium-priced 1-injection products will continue to become more popular over the forecast period, 3- and 5-injection products will continue to be preferred in some countries due to differences in product access, cost, and reimbursement.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for the US, Europe, Asia Pacific, and Brazil across a 10-year period.
The COVID-19 pandemic will affect the HA viscosupplementation market.
To what extent will COVID-19 impact the HA viscosupplementation market globally?
How quickly are procedure volumes expected to recover?
The continuing introduction of 1-injection products and expanded indications in the HA viscosupplementation market will drive market growth.
How will the introduction of new products with more clinical data supporting the efficacy of HA treatment affect procedure volumes?
How fast are different geographies moving toward shorter treatment regimens, and how will the adoption of 1-injection products impact the market in the upcoming years?
Reimbursement for HA injections is facing greater scrutiny in Europe.
Which countries have limited or a complete lack of reimbursement for these products?
What strategies can companies use to promote their products when reimbursement is lacking?
In the Asia Pacific region, domestic manufacturers have gained popularity.
What are the factors influencing HA viscosupplementation product adoption among these competitors?
How are domestic manufacturers' product offerings evolving?
How will government initiatives affect the competitiveness of domestic companies?
In which countries do domestic companies hold particularly high market shares and why?
- Hyaluronic Acid Viscosupplementation - Market Insights - Global
Author(s): Swarnadip Dutta, MBA
Swarnadip Dutta is a team lead within the Orthopedics, Dental, and Aesthetics Medtech Insights team at Decision Resources Group, specializing in the fields of dental implants, joint reconstruction, and craniomaxillofacial devices. Swarnadip holds a Master's degree in Bioinformatics and Biotechnology from SRM University, an MBA in Operations Management, and a Six Sigma Green Belt certification from the Indian Statistical Institute.
Follow Swarnadip on Twitter: @Swarnadip_DRG.